4.2 Article

The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus

Journal

CURRENT RHEUMATOLOGY REPORTS
Volume 21, Issue 1, Pages -

Publisher

SPRINGER
DOI: 10.1007/s11926-019-0801-5

Keywords

SLE; GWAS; iPSC; Humanized mice

Categories

Funding

  1. National Institutes of Health [RO1A1091670, R21AI128111]
  2. Department of Defense [PR130012, LR170078]
  3. Lupus Research Alliance Grant [LRA548931]

Ask authors/readers for more resources

Purpose of ReviewSystemic lupus erythematosus (SLE) is a complex autoimmune disease with strong genetic associations. Here, we provide an update on recent advancements in validating SLE candidate genes and risk variants identified in genome-wide association studies (GWAS).Recent FindingsA pairing of computational biology with new and emerging techniques has significantly increased our understanding of SLE associated variants. Specifically, generation of mutations within mice and examination of patient samples has been the dominant mechanisms for variant validation.SummaryWhile progress has been made in validating some genes, the number of associated genes is growing with minimal exploration of the effects of individual variants on SLE. This indicates that further examination of SLE risk variants in a cell-type-specific manner is required for better understanding of their contributions to SLE disease mechanisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available